| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bruno B Ortiz, Cinthia H Higuchi, Cristiano Noto, Dan W Joyce, Christoph U Correll, Rodrigo A Bressan, Ary Gadelh. A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice. Schizophrenia research. vol 218. 2021-06-17. PMID:31956005. |
early identification of symptoms that can predict treatment-resistant schizophrenia (trs) could help clinicians to avoid delays in clozapine therapy. |
2021-06-17 |
2023-08-13 |
Not clear |
| Meha Verma, Swapnajeet Sahoo, Ritu Nehra, Sandeep Grove. Does clozapine improves cognition in patients with treatment resistant schizophrenia?: An exploratory study. Schizophrenia research. vol 218. 2021-06-17. PMID:32063439. |
does clozapine improves cognition in patients with treatment resistant schizophrenia? |
2021-06-17 |
2023-08-13 |
Not clear |
| Georgios Schoretsanitis, Alan Mendelowitz, Chitra Malur, Raphael J Braga, Nina R Schooler, Majnu John, Jose de Leon, John M Kane, Georgios Petride. Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. Schizophrenia research. vol 218. 2021-06-17. PMID:32107101. |
lack of ect effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: pharmacokinetic evidence from a randomized clinical trial. |
2021-06-17 |
2023-08-13 |
Not clear |
| Susanna Every-Palmer, Stephen J Inns, Pete M Elli. Constipation screening in people taking clozapine: A diagnostic accuracy study. Schizophrenia research. vol 220. 2021-06-17. PMID:32245597. |
clozapine is the favoured antipsychotic for treatment-refractory schizophrenia but its safe use requires careful adverse-effect management. |
2021-06-17 |
2023-08-13 |
Not clear |
| Eric Kelleher, Patricia McNamara, Jean Dunne, Brian Fitzmaurice, Elizabeth A Heron, Peter Whitty, Richard Walsh, Christina Mooney, Denise Hogan, Niall Conlon, Michael Gill, Angela Vincent, Colin P Doherty, Aiden Corvi. Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophrenia research. vol 222. 2021-06-17. PMID:32499165. |
prevalence of n-methyl-d-aspartate receptor antibody (nmdar-ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. |
2021-06-17 |
2023-08-13 |
Not clear |
| Eric Kelleher, Patricia McNamara, Jean Dunne, Brian Fitzmaurice, Elizabeth A Heron, Peter Whitty, Richard Walsh, Christina Mooney, Denise Hogan, Niall Conlon, Michael Gill, Angela Vincent, Colin P Doherty, Aiden Corvi. Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophrenia research. vol 222. 2021-06-17. PMID:32499165. |
we aimed to examine the prevalence of nmdar-ab encephalitis in patients with first episode psychosis (fep) and treatment resistant schizophrenia (trs) on clozapine, using clinical investigations, antibody testing and to retrospectively apply diagnostic consensus criteria. |
2021-06-17 |
2023-08-13 |
Not clear |
| Kirill Masychev, Claudio Ciprian, Maryam Ravan, Akshaya Manimaran, AnkitaAmol Deshmuk. Quantitative biomarkers to predict response to clozapine treatment using resting EEG data. Schizophrenia research. vol 223. 2021-06-17. PMID:32928617. |
clozapine is an anti-psychotic drug that is known to be effective in the treatment of patients with chronic treatment-resistant schizophrenia (trs-scz), commonly estimated to be around one third of all cases. |
2021-06-17 |
2023-08-13 |
Not clear |
| Mattia Campana, Peter Falkai, Dan Siskind, Alkomiet Hasan, Elias Wagne. Characteristics and definitions of ultra-treatment-resistant schizophrenia - A systematic review and meta-analysis. Schizophrenia research. vol 228. 2021-06-17. PMID:33454644. |
the aim of this systematic review and meta-analysis was to characterize ultra-treatment-resistant schizophrenia also known as clozapine-resistant schizophrenia (crs) patients across clozapine combination and augmentation trials through demographic and clinical baseline data. |
2021-06-17 |
2023-08-13 |
Not clear |
| Hetal P Patel, Priyanka S Chaudhari, Priyanshi A Gandhi, Bhargavi V Desai, Ditixa T Desai, Praful P Dedhiya, Bhavin A Vyas, Furqan A Maulv. Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies. International journal of pharmaceutics. vol 600. 2021-06-17. PMID:33737093. |
clozapine is widely used to treat schizophrenia as an atypical antipsychotic. |
2021-06-17 |
2023-08-13 |
Not clear |
| Virginie Moulier, Mohamed Wassim Krir, Marine Dalmont, Olivier Guillin, Maud Rothärme. A prospective multicenter assessor-blinded randomized controlled study to compare the efficacy of short versus long protocols of electroconvulsive therapy as an augmentation strategy to clozapine in patients with ultra-resistant schizophrenia (SURECT study). Trials. vol 22. issue 1. 2021-06-17. PMID:33858488. |
a prospective multicenter assessor-blinded randomized controlled study to compare the efficacy of short versus long protocols of electroconvulsive therapy as an augmentation strategy to clozapine in patients with ultra-resistant schizophrenia (surect study). |
2021-06-17 |
2023-08-13 |
Not clear |
| Virginie Moulier, Mohamed Wassim Krir, Marine Dalmont, Olivier Guillin, Maud Rothärme. A prospective multicenter assessor-blinded randomized controlled study to compare the efficacy of short versus long protocols of electroconvulsive therapy as an augmentation strategy to clozapine in patients with ultra-resistant schizophrenia (SURECT study). Trials. vol 22. issue 1. 2021-06-17. PMID:33858488. |
our objective is to compare the efficacy and tolerance between two protocols of combined ect and clozapine treatment in patients with ultra-resistant schizophrenia (urs): a 6-month protocol (short protocol with 20 ect sessions) and a 12-month protocol (long protocol with 40 ect sessions). |
2021-06-17 |
2023-08-13 |
Not clear |
| Rikinkumar S Patel, Nikhila Veluri, Alex Suchorab, Kaushal Shah, Geetika Verm. Clozapine-Induced Constipation: A Case Report and Review of Current Management Guidelines. Cureus. vol 13. issue 5. 2021-06-15. PMID:34123610. |
clozapine is a second-generation antipsychotic recommended after the failure of two or more antipsychotics for treatment-resistant schizophrenia. |
2021-06-15 |
2023-08-13 |
Not clear |
| Dragana Ignjatovic Ristic, Dan Cohen, Ivan Risti. Prescription attitudes and practices regarding clozapine among Serbian psychiatrists: results of a nationwide survey. Therapeutic advances in psychopharmacology. vol 11. 2021-06-11. PMID:34104415. |
despite clozapine being the most effective treatment for treatment-resistant schizophrenia (trs), a clear explanation as to why it is underutilized and why its initiation is delayed remains unclear. |
2021-06-11 |
2023-08-13 |
Not clear |
| Michelle Iris Jakobsen, H Grønborg, H V Hansen, A Fink-Jense. Clozapine-associated neutropenia following augmentation with sodium valproate. SAGE open medical case reports. vol 9. 2021-06-11. PMID:34104448. |
clozapine is gold standard for the management of treatment-resistant schizophrenia. |
2021-06-11 |
2023-08-13 |
Not clear |
| Atsuhiro Miyazawa, Nobuhisa Kanahara, Yusuke Nakata, Satoshi Kodama, Hiroshi Kimura, Atsushi Kimura, Yasunori Oda, Hiroyuki Watanabe, Masaomi Iy. Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia. Psychopharmacology bulletin. vol 51. issue 2. 2021-06-08. PMID:34092820. |
clozapine prolongs cortical silent period in patients with treatment-resistant schizophrenia. |
2021-06-08 |
2023-08-13 |
Not clear |
| Atsuhiro Miyazawa, Nobuhisa Kanahara, Yusuke Nakata, Satoshi Kodama, Hiroshi Kimura, Atsushi Kimura, Yasunori Oda, Hiroyuki Watanabe, Masaomi Iy. Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia. Psychopharmacology bulletin. vol 51. issue 2. 2021-06-08. PMID:34092820. |
although clozapine exhibited high efficacy for treating the symptoms of patients with treatment-resistant schizophrenia (trs), its precise action mechanisms have not been fully understood. |
2021-06-08 |
2023-08-13 |
Not clear |
| Rachel Grimminck, Oloruntoba Oluboka, Manvir Sihota, Donna L Rutherford, Helen Yeun. Combination of Clozapine With Long-Acting Injectable Antipsychotics in Treatment-Resistant Schizophrenia: Preliminary Evidence From Health Care Utilization Indices. The primary care companion for CNS disorders. vol 22. issue 4. 2021-06-07. PMID:32678523. |
combination of clozapine with long-acting injectable antipsychotics in treatment-resistant schizophrenia: preliminary evidence from health care utilization indices. |
2021-06-07 |
2023-08-13 |
Not clear |
| Rachel Grimminck, Oloruntoba Oluboka, Manvir Sihota, Donna L Rutherford, Helen Yeun. Combination of Clozapine With Long-Acting Injectable Antipsychotics in Treatment-Resistant Schizophrenia: Preliminary Evidence From Health Care Utilization Indices. The primary care companion for CNS disorders. vol 22. issue 4. 2021-06-07. PMID:32678523. |
clozapine is indicated for treatment-resistant schizophrenia (trs), but only 30%-60% of patients will respond. |
2021-06-07 |
2023-08-13 |
Not clear |
| Basel A Abdel-Wahab, Safaa Yousef Salem, Hala Mostafa Mohammed, Nashwa Ahmed Mohammed, Helal F Hett. The role of vimentin, Connexin-43 proteins, and oxidative stress in the protective effect of propranolol against clozapine-induced myocarditis and apoptosis in rats. European journal of pharmacology. vol 890. 2021-06-07. PMID:33098837. |
clozapine (clz) represents an effective treatment for resistant schizophrenia. |
2021-06-07 |
2023-08-13 |
rat |
| Shinwon Kang, Hyun Jong Noh, Soo Hyeon Bae, Yong-Seok Kim, Hogun Lew, Jisoo Lim, Se Joo Kim, Kyung Sue Hong, Jong-Cheol Rah, Chul Hoon Ki. Clozapine generates obsessive compulsive disorder-like behavior in mice. Molecular brain. vol 13. issue 1. 2021-06-04. PMID:32471517. |
however, because ocs are often comorbid with schizophrenia regardless of clozapine treatment, it remains unclear whether clozapine can generate ocs de novo. |
2021-06-04 |
2023-08-13 |
mouse |